Company intelligence / Profile preview

Alcobra Ltd.

Tel Aviv, Tel Aviv District, Israelalcobra.de ↗

Ownership: Private
Development stage: Other

Overview

Alcobra Ltd. was an Israeli biopharmaceutical company focused primarily on developing Metadoxine Extended Release (MDX) for ADHD and Fragile X. In January 2017 it suspended most R&D after a clinical hold affecting its lead program. In September 2017 it merged with Arcturus Therapeutics Inc., shifting focus to RNA medicines including mRNA vaccines/therapies targeting infectious diseases and rare genetic disorders. The combined entity is now known as Arcturus Therapeutics Holdings Inc., NASDAQ symbol ARCT.[2]

Therapeutic areas: PsychiatryInfectious Diseases
Modalities: Small molecules (notably Metadoxine/MDX for CNS disorders)[5][8]mRNA and saRNA vaccines/therapeutics (post-merger with Arcturus Therapeutics)[4][6]Prophylactic vaccines[4]
Industry: Biotech

Partnerships

Arcturus has partnerships with major pharmaceutical companies supporting several pipeline programs post-merger,[2] though specific partners are not listed here.

Beyond the preview

Go deeper on Alcobra Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alcobra Ltd..

Explore the full profile